Remed Co

Remed Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Remed Co (302550.KQ) as of Oct 28, 2026 is 88.75 %. In the previous year, Operating Cash Flow to Debt Ratio was 16.46 % — a change of 439.31% (higher).

OCF/Debt

88.75 %

YoY

439.31%

Last updated:

Operating Cash Flow to Debt Ratio of Remed Co is 2025 88.75 % . Operating Cash Flow to Debt Ratio of Remed Co was 2024 16.46 % . It decreases by 439.31% higher compared to the previous year.

The Remed Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
-4.80 KRW
Jan 1, 2019
55.01 KRW
Jan 1, 2020
13.72 KRW
Jan 1, 2021
-17.83 KRW
Jan 1, 2022
102.81 KRW
Jan 1, 2023
19.87 KRW
Jan 1, 2024
16.46 KRW
Jan 1, 2025
88.75 KRW
The Remed Co OCF/Debt history
YEAROCF/DebtYoY
88.75 %+439.31%
16.46 %-17.17%
19.87 %-80.68%
102.81 %-676.49%
-17.83 %-230.02%
13.72 %-75.07%
55.01 %-1,244.99%
-4.80 %-427.68%
1.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Operating Cash Flow to Debt Ratio of Remed Co is 88.75 % in 2025.

Operating Cash Flow to Debt Ratio of Remed Co changed from 16.46 % to 88.75 %, representing a 439.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Remed Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Remed Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Remed Co

All Key Metrics — Remed Co